害怕错过:美国和加拿大的药物供应。

IF 2.3 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Mina Tadrous, Clara Chen, Katherine Callaway Kim, Martin Ho, Joel Lexchin, Inmaculada Hernandez, Katie J Suda
{"title":"害怕错过:美国和加拿大的药物供应。","authors":"Mina Tadrous, Clara Chen, Katherine Callaway Kim, Martin Ho, Joel Lexchin, Inmaculada Hernandez, Katie J Suda","doi":"10.18553/jmcp.2024.30.12.1349","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Per capita spending on drugs in the United States is double that of Canada. One commonly debated point when comparing the 2 countries is whether this additional spending allows residents of the United States access to valuable therapies not available in Canada.</p><p><strong>Objective: </strong>To characterize the therapeutic value of prescription drugs used in the United States that are not marketed in Canada.</p><p><strong>Methods: </strong>This cross-sectional study used IQVIA Multinational Integrated Data Analysis System data to identify drugs purchased in the United States but not in Canada from 2017 to 2021. Drug listing and regulatory review statuses were obtained. We categorized the drugs into 8 mutually exclusive groups: listing status in Canada (\"cancelled post-market\" or \"dormant; approved but not marketed; cancelled pre-market\"), other alternatives available (\"formulation unavailable,\" \"existing drug class,\" or \"therapeutically similar\"), \"pre-approval,\" \"atypical access available,\" or \"unavailable without alternatives marketed\" in Canada. Therapeutic value assessments of drugs in the last category were obtained from 3 international organizations.</p><p><strong>Results: </strong>2,084 products were purchased in the United States but not in Canada from 2017 to 2021; 1,685 were excluded because they were not prescription drugs, were combinations in which each active pharmaceutical ingredient was already available in the United States as a separate drug, had been discontinued in the United States by August 30, 2023, or were marketed in Canada by August 30, 2023. After exclusions, there were 399 drugs; 120 (30%) were \"cancelled post-market,\" 38 (10%) were \"dormant; approved but not marketed; cancelled pre-market,\" 49 (12%) were \"formulation unavailable,\" 130 (33%) were \"existing drug class,\" 35 (9%) were \"therapeutically similar,\" 3 (1%) were \"preapproval,\" 15 (4%) were \"atypical access available,\" and 9 (2%) were \"unavailable\" in Canada. 6 of the 9 drugs had been evaluated by 1 or more independent organizations, and all 6 were rated as offering minor to no additional therapeutic value compared with existing drugs.</p><p><strong>Conclusions: </strong>There was similar access to important prescription drug therapies in the United States and Canada. Overall, the additional spending in the United States may not have necessarily translated into access to important therapeutic innovations.</p>","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"30 12","pages":"1349-1354"},"PeriodicalIF":2.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607214/pdf/","citationCount":"0","resultStr":"{\"title\":\"Fear of missing out: Drug availability in the United States vs Canada.\",\"authors\":\"Mina Tadrous, Clara Chen, Katherine Callaway Kim, Martin Ho, Joel Lexchin, Inmaculada Hernandez, Katie J Suda\",\"doi\":\"10.18553/jmcp.2024.30.12.1349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Per capita spending on drugs in the United States is double that of Canada. One commonly debated point when comparing the 2 countries is whether this additional spending allows residents of the United States access to valuable therapies not available in Canada.</p><p><strong>Objective: </strong>To characterize the therapeutic value of prescription drugs used in the United States that are not marketed in Canada.</p><p><strong>Methods: </strong>This cross-sectional study used IQVIA Multinational Integrated Data Analysis System data to identify drugs purchased in the United States but not in Canada from 2017 to 2021. Drug listing and regulatory review statuses were obtained. We categorized the drugs into 8 mutually exclusive groups: listing status in Canada (\\\"cancelled post-market\\\" or \\\"dormant; approved but not marketed; cancelled pre-market\\\"), other alternatives available (\\\"formulation unavailable,\\\" \\\"existing drug class,\\\" or \\\"therapeutically similar\\\"), \\\"pre-approval,\\\" \\\"atypical access available,\\\" or \\\"unavailable without alternatives marketed\\\" in Canada. Therapeutic value assessments of drugs in the last category were obtained from 3 international organizations.</p><p><strong>Results: </strong>2,084 products were purchased in the United States but not in Canada from 2017 to 2021; 1,685 were excluded because they were not prescription drugs, were combinations in which each active pharmaceutical ingredient was already available in the United States as a separate drug, had been discontinued in the United States by August 30, 2023, or were marketed in Canada by August 30, 2023. After exclusions, there were 399 drugs; 120 (30%) were \\\"cancelled post-market,\\\" 38 (10%) were \\\"dormant; approved but not marketed; cancelled pre-market,\\\" 49 (12%) were \\\"formulation unavailable,\\\" 130 (33%) were \\\"existing drug class,\\\" 35 (9%) were \\\"therapeutically similar,\\\" 3 (1%) were \\\"preapproval,\\\" 15 (4%) were \\\"atypical access available,\\\" and 9 (2%) were \\\"unavailable\\\" in Canada. 6 of the 9 drugs had been evaluated by 1 or more independent organizations, and all 6 were rated as offering minor to no additional therapeutic value compared with existing drugs.</p><p><strong>Conclusions: </strong>There was similar access to important prescription drug therapies in the United States and Canada. Overall, the additional spending in the United States may not have necessarily translated into access to important therapeutic innovations.</p>\",\"PeriodicalId\":16170,\"journal\":{\"name\":\"Journal of managed care & specialty pharmacy\",\"volume\":\"30 12\",\"pages\":\"1349-1354\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11607214/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of managed care & specialty pharmacy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.18553/jmcp.2024.30.12.1349\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of managed care & specialty pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18553/jmcp.2024.30.12.1349","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景:美国的人均药品支出是加拿大的两倍。在比较这两个国家时,一个经常争论的问题是,这笔额外的支出是否允许美国居民获得加拿大无法获得的有价值的治疗。目的:表征在美国使用的未在加拿大销售的处方药的治疗价值。方法:本横断面研究使用IQVIA跨国综合数据分析系统数据识别2017年至2021年在美国购买但未在加拿大购买的药物。获得药品清单和监管审查状态。我们将这些药物分为8个相互排斥的组:在加拿大的上市状态(“上市后取消”或“休眠”;已批准但未上市;取消上市前”),其他可获得的替代品(“配方不可用”,“现有药物类别”或“治疗类似”),“预批准”,“非典型可及性”或“在加拿大无替代品销售时不可获得”。最后一类药物的治疗价值评估来自3个国际组织。结果:2017年至2021年,在美国购买了2084种产品,但在加拿大没有购买;1,685种被排除在外,因为它们不是处方药,是每种活性药物成分在美国已经作为单独药物存在的组合,在2023年8月30日之前已经在美国停售,或者在2023年8月30日之前在加拿大上市。排除后,有399种药物;120家(30%)“上市后取消”,38家(10%)“休眠”;已批准但未上市;取消上市前,49种(12%)是“配方不可用”,130种(33%)是“现有药物类别”,35种(9%)是“治疗相似”,3种(1%)是“预批准”,15种(4%)是“非典型可及性”,9种(2%)是“不可用”在加拿大。9种药物中的6种已被一个或多个独立组织评估,所有6种药物被评为与现有药物相比提供少量或无额外治疗价值。结论:在美国和加拿大,重要处方药治疗的可及性相似。总的来说,美国的额外支出可能不一定转化为获得重要的治疗创新。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Fear of missing out: Drug availability in the United States vs Canada.

Background: Per capita spending on drugs in the United States is double that of Canada. One commonly debated point when comparing the 2 countries is whether this additional spending allows residents of the United States access to valuable therapies not available in Canada.

Objective: To characterize the therapeutic value of prescription drugs used in the United States that are not marketed in Canada.

Methods: This cross-sectional study used IQVIA Multinational Integrated Data Analysis System data to identify drugs purchased in the United States but not in Canada from 2017 to 2021. Drug listing and regulatory review statuses were obtained. We categorized the drugs into 8 mutually exclusive groups: listing status in Canada ("cancelled post-market" or "dormant; approved but not marketed; cancelled pre-market"), other alternatives available ("formulation unavailable," "existing drug class," or "therapeutically similar"), "pre-approval," "atypical access available," or "unavailable without alternatives marketed" in Canada. Therapeutic value assessments of drugs in the last category were obtained from 3 international organizations.

Results: 2,084 products were purchased in the United States but not in Canada from 2017 to 2021; 1,685 were excluded because they were not prescription drugs, were combinations in which each active pharmaceutical ingredient was already available in the United States as a separate drug, had been discontinued in the United States by August 30, 2023, or were marketed in Canada by August 30, 2023. After exclusions, there were 399 drugs; 120 (30%) were "cancelled post-market," 38 (10%) were "dormant; approved but not marketed; cancelled pre-market," 49 (12%) were "formulation unavailable," 130 (33%) were "existing drug class," 35 (9%) were "therapeutically similar," 3 (1%) were "preapproval," 15 (4%) were "atypical access available," and 9 (2%) were "unavailable" in Canada. 6 of the 9 drugs had been evaluated by 1 or more independent organizations, and all 6 were rated as offering minor to no additional therapeutic value compared with existing drugs.

Conclusions: There was similar access to important prescription drug therapies in the United States and Canada. Overall, the additional spending in the United States may not have necessarily translated into access to important therapeutic innovations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of managed care & specialty pharmacy
Journal of managed care & specialty pharmacy Health Professions-Pharmacy
CiteScore
3.50
自引率
4.80%
发文量
131
期刊介绍: JMCP welcomes research studies conducted outside of the United States that are relevant to our readership. Our audience is primarily concerned with designing policies of formulary coverage, health benefit design, and pharmaceutical programs that are based on evidence from large populations of people. Studies of pharmacist interventions conducted outside the United States that have already been extensively studied within the United States and studies of small sample sizes in non-managed care environments outside of the United States (e.g., hospitals or community pharmacies) are generally of low interest to our readership. However, studies of health outcomes and costs assessed in large populations that provide evidence for formulary coverage, health benefit design, and pharmaceutical programs are of high interest to JMCP’s readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信